JP2016511637A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511637A5 JP2016511637A5 JP2015557139A JP2015557139A JP2016511637A5 JP 2016511637 A5 JP2016511637 A5 JP 2016511637A5 JP 2015557139 A JP2015557139 A JP 2015557139A JP 2015557139 A JP2015557139 A JP 2015557139A JP 2016511637 A5 JP2016511637 A5 JP 2016511637A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- positions
- light chain
- heavy chain
- immunoconjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 91
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 91
- 229940127121 immunoconjugate Drugs 0.000 claims description 66
- 238000006467 substitution reaction Methods 0.000 claims description 45
- 235000018417 cysteine Nutrition 0.000 claims description 39
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 35
- 235000001014 amino acid Nutrition 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 19
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 239000011593 sulfur Substances 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 239000002458 cell surface marker Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000012624 DNA alkylating agent Substances 0.000 claims description 2
- 229940123237 Taxane Drugs 0.000 claims description 2
- 102000004243 Tubulin Human genes 0.000 claims description 2
- 108090000704 Tubulin Proteins 0.000 claims description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical class COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 241000182341 Cubitermes group Species 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 22
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 9
- 229960000575 trastuzumab Drugs 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 150000001945 cysteines Chemical class 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- LGNCNVVZCUVPOT-FUVGGWJZSA-N (2s)-2-[[(2r,3r)-3-[(2s)-1-[(3r,4s,5s)-4-[[(2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 LGNCNVVZCUVPOT-FUVGGWJZSA-N 0.000 description 1
- 229940126161 DNA alkylating agent Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010405 reoxidation reaction Methods 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361762563P | 2013-02-08 | 2013-02-08 | |
| US61/762,563 | 2013-02-08 | ||
| PCT/US2014/015393 WO2014124316A2 (en) | 2013-02-08 | 2014-02-07 | Specific sites for modifying antibodies to make immunoconjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016511637A JP2016511637A (ja) | 2016-04-21 |
| JP2016511637A5 true JP2016511637A5 (enExample) | 2017-03-16 |
| JP6609477B2 JP6609477B2 (ja) | 2019-11-20 |
Family
ID=50179939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015557139A Active JP6609477B2 (ja) | 2013-02-08 | 2014-02-07 | イムノコンジュゲートを調製する修飾抗体のための特定部位 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20160067351A1 (enExample) |
| EP (2) | EP2953976B1 (enExample) |
| JP (1) | JP6609477B2 (enExample) |
| KR (3) | KR102626525B1 (enExample) |
| CN (2) | CN105143271A (enExample) |
| AU (2) | AU2014214751B2 (enExample) |
| BR (1) | BR112015018899B1 (enExample) |
| CA (1) | CA2900755C (enExample) |
| DK (1) | DK2953976T3 (enExample) |
| EA (1) | EA201591465A1 (enExample) |
| ES (1) | ES2874493T3 (enExample) |
| HU (1) | HUE054443T2 (enExample) |
| IL (1) | IL240406B (enExample) |
| MX (2) | MX2015010146A (enExample) |
| PL (1) | PL2953976T3 (enExample) |
| PT (1) | PT2953976T (enExample) |
| SG (2) | SG11201506025RA (enExample) |
| SI (1) | SI2953976T1 (enExample) |
| WO (1) | WO2014124316A2 (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3539982B1 (en) | 2011-12-23 | 2025-02-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| KR20210132742A (ko) | 2012-12-21 | 2021-11-04 | 알트루바이오 인코퍼레이티드 | 친수성 자기-희생 링커 및 그것의 포합체 |
| EA201591465A1 (ru) | 2013-02-08 | 2015-12-30 | АйАрЭм ЭлЭлСи | Специфичные участки для модификации антител для получения иммуноконъюгатов |
| JP2016531915A (ja) | 2013-08-28 | 2016-10-13 | ステムセントリックス， インコーポレイテッド | 部位特異的抗体コンジュゲーション方法および組成物 |
| AU2014346792A1 (en) | 2013-11-06 | 2016-06-02 | Abbvie Stemcentrx Llc | Novel anti-claudin antibodies and methods of use |
| KR20160097336A (ko) | 2013-12-12 | 2016-08-17 | 스템센트알엑스 인코포레이티드 | 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법 |
| WO2015095301A2 (en) | 2013-12-17 | 2015-06-25 | Irm Llc | Cytotoxic peptides and conjugates thereof |
| EP3107576A4 (en) | 2014-02-21 | 2017-09-06 | Abbvie Stemcentrx LLC | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| BR112016020065A2 (pt) * | 2014-03-12 | 2018-02-20 | Novartis Ag | sítios específicos para modificar anticorpos para fazer imunoconjugados |
| ES2719584T3 (es) * | 2014-04-11 | 2019-07-11 | Medimmune Llc | Compuestos conjugados que comprenden anticuerpos modificados por ingeniería genética con cisteína |
| DK3151865T3 (da) | 2014-05-22 | 2021-10-25 | Byondis Bv | Stedsspecifik konjugation af linker medicin til antistof og resulterende adcs |
| WO2015196089A1 (en) * | 2014-06-20 | 2015-12-23 | Bioalliance C.V. | Anti-cd22 antibody-drug conjugates and methods of using thereof |
| KR20170020868A (ko) | 2014-06-20 | 2017-02-24 | 바이오얼라이언스 씨.브이. | 항-폴레이트 수용체 알파 (fra) 항체-약물 컨쥬게이트 및 그것의 사용 방법 |
| CA2952834A1 (en) * | 2014-06-20 | 2015-12-23 | Abgenomics International Inc. | Her2 antibody-drug conjugates |
| TW201617368A (zh) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗ｍｆｉ２抗體及使用方法 |
| JP2017531620A (ja) * | 2014-09-12 | 2017-10-26 | ジェネンテック， インコーポレイテッド | システイン操作抗体及びコンジュゲート |
| AU2015366284B2 (en) | 2014-12-19 | 2021-07-22 | Ablynx N.V. | Cysteine linked nanobody dimers |
| KR102672113B1 (ko) * | 2015-02-16 | 2024-06-03 | 론자 리미티드 | Cl 및/또는 ch1 돌연변이된 약물 접합용 항체 |
| US20190194315A1 (en) | 2015-06-17 | 2019-06-27 | Novartis Ag | Antibody drug conjugates |
| CR20180229A (es) | 2015-10-29 | 2018-08-24 | Novartis Ag | Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll |
| TWI812873B (zh) * | 2015-11-30 | 2023-08-21 | 美商輝瑞股份有限公司 | 用於部位專一性接合之抗體和抗體片段 |
| US10689458B2 (en) * | 2015-11-30 | 2020-06-23 | Pfizer Inc. | Site specific HER2 antibody drug conjugates |
| US20180271998A1 (en) | 2015-12-04 | 2018-09-27 | Merrimack Pharmaceuticals, Inc. | Disulfide-stabilized fabs |
| EP3394096A1 (en) | 2015-12-21 | 2018-10-31 | Bristol-Myers Squibb Company | Variant antibodies for site-specific conjugation |
| WO2017120534A1 (en) | 2016-01-08 | 2017-07-13 | Bioalliance C.V. | Tetravalent anti-psgl-1 antibodies and uses thereof |
| BR112019000071A2 (pt) | 2016-07-07 | 2019-07-02 | Bolt Biotherapeutics Inc | conjugados adjuvantes de anticorpo |
| CN118846112A (zh) * | 2016-10-08 | 2024-10-29 | 四川百利药业有限责任公司 | 半胱氨酸改造的抗体-毒素偶联物及其制备方法 |
| EP3525826B1 (en) | 2016-10-11 | 2020-07-22 | Byondis B.V | Non-linear self-immolative linkers and conjugates thereof |
| IL310865A (en) | 2016-10-17 | 2024-04-01 | Pfizer | Antibodies against EDB and antibody-drug conjugates |
| WO2018106645A1 (en) * | 2016-12-07 | 2018-06-14 | Innate Biotherapeutics, Llc | β-1,6-GLUCAN THERAPEUTIC ANTIBODY CONJUGATES |
| CN117653740A (zh) | 2016-12-21 | 2024-03-08 | 诺华股份有限公司 | 用于消融造血干细胞的抗体药物缀合物 |
| JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| IL298414B2 (en) * | 2017-02-28 | 2024-12-01 | Immunogen Inc | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof |
| SG11201907288RA (en) * | 2017-02-28 | 2019-09-27 | Seattle Genetics Inc | Cysteine mutated antibodies for conjugation |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| AR111651A1 (es) | 2017-04-28 | 2019-08-07 | Novartis Ag | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
| AR113224A1 (es) * | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| US20200155702A1 (en) * | 2017-06-16 | 2020-05-21 | Eli Lilly And Company | Engineered Antibody Compounds and Conjuates Thereof |
| CN108743968B (zh) * | 2017-06-20 | 2022-04-19 | 成都百利多特生物药业有限责任公司 | 半胱氨酸改造的抗体-毒素偶联物(tdc)定点偶联位点筛选 |
| JP7117088B2 (ja) * | 2017-08-04 | 2022-08-12 | シスメックス株式会社 | 抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法 |
| US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
| JP7543134B2 (ja) * | 2017-10-03 | 2024-09-02 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | システイン操作された抗原結合分子 |
| PE20210320A1 (es) | 2018-06-01 | 2021-02-16 | Novartis Ag | Moleculas de union contra bcma y usos de las mismas |
| UY38265A (es) | 2018-06-20 | 2020-01-31 | Novartis Ag | Conjugados anticuerpo droga para ablación de células madre hematopoyéticas |
| WO2020089815A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Antibody conjugates comprising sting agonist |
| EP3873532A1 (en) | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign antibody drug conjugates |
| AU2019409132B2 (en) | 2018-12-21 | 2026-08-06 | Novartis Ag | Antibodies to PMEL17 and conjugates thereof |
| CN111675762B (zh) * | 2019-03-11 | 2023-12-01 | 凯惠科技发展(上海)有限公司 | 一种含半胱氨酸的抗体、药物偶联物及其应用 |
| EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| AU2020279979A1 (en) | 2019-05-20 | 2021-11-25 | Les Laboratoires Servier | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| CA3140063A1 (en) | 2019-05-20 | 2020-11-26 | Novartis Ag | Antibody drug conjugates having linkers comprising hydrophilic groups |
| KR20220079590A (ko) | 2019-10-04 | 2022-06-13 | 티에이이 라이프 사이언시스 | Fc 돌연변이 및 부위-특이적인 접합 성질을 포함하는 항체 조성물 |
| AU2021225962A1 (en) * | 2020-02-28 | 2022-10-20 | Genzyme Corporation | Modified binding polypeptides for optimized drug conjugation |
| US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
| JP2023553808A (ja) | 2020-11-24 | 2023-12-26 | ノバルティス アーゲー | Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法 |
| CN116761635A (zh) | 2020-11-24 | 2023-09-15 | 诺华股份有限公司 | Bcl-xl抑制剂抗体药物缀合物及其使用方法 |
| MX2023006010A (es) | 2020-11-24 | 2023-06-08 | Novartis Ag | Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos. |
| CN118221804B (zh) * | 2021-01-18 | 2025-02-07 | 上海药明合联生物技术有限公司 | 工程化抗体和包含工程化抗体的抗体-药物偶联物 |
| EP4294453B1 (en) | 2021-02-16 | 2026-07-29 | Glykos Finland Oy | Linker-payloads and conjugates thereof |
| AU2022258829A1 (en) | 2021-04-16 | 2023-10-26 | Novartis Ag | Antibody drug conjugates and methods for making thereof |
| US20250000995A1 (en) * | 2021-10-29 | 2025-01-02 | Bolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
| IL317101A (en) | 2022-05-20 | 2025-01-01 | Novartis Ag | Antibody-drug conjugates of anticancer compounds and methods of using them |
| CN119562832A (zh) | 2022-05-20 | 2025-03-04 | 诺华股份有限公司 | Met bcl-xl抑制剂抗体-药物缀合物及其使用方法 |
| EP4525925A1 (en) | 2022-05-20 | 2025-03-26 | Novartis AG | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| CN120187743A (zh) * | 2022-11-08 | 2025-06-20 | 西湖大学 | 多肽标签、组合物及用于蛋白质位点特异性偶联的方法 |
| WO2024129756A1 (en) | 2022-12-13 | 2024-06-20 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| EP4676540A1 (en) | 2023-03-10 | 2026-01-14 | Novartis AG | Panras inhibitor antibody-drug conjugates and methods of use thereof |
| CN118837542A (zh) * | 2023-04-24 | 2024-10-25 | 菲鹏生物股份有限公司 | 抗体和抗体缀合物及其用途 |
| AU2024304180A1 (en) | 2023-06-13 | 2026-01-08 | Adcentrx Therapeutics, Inc. | Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins |
| WO2025019790A1 (en) | 2023-07-19 | 2025-01-23 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with trop-2 targeting adc |
| CN119375471A (zh) * | 2023-07-26 | 2025-01-28 | 菲鹏生物股份有限公司 | 抗体和抗体缀合物及其用途 |
| TW202513593A (zh) * | 2023-09-08 | 2025-04-01 | 大陸商信達生物製藥（蘇州）有限公司 | 半胱胺酸改造的抗體和免疫綴合物 |
| UY40985A (es) | 2023-11-22 | 2025-06-30 | Servier Lab | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos |
| AR134424A1 (es) | 2023-11-22 | 2026-01-14 | Novartis Ag | Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos |
| WO2025264533A1 (en) | 2024-06-17 | 2025-12-26 | Adcentrx Therapeutics Inc. | Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins |
| TW202617186A (zh) | 2024-06-28 | 2026-05-01 | 美商飛爾富來生物公司 | Ｂｃｌ－ｘｌ降解劑抗體結合物及其用途 |
| EP4706675A1 (en) * | 2024-09-10 | 2026-03-11 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Cysteine-engineered chimeric antigen receptor |
| EP4706676A1 (en) * | 2024-09-10 | 2026-03-11 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Cysteine-engineered antigen-binding domains |
Family Cites Families (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2429008A (en) | 1945-12-01 | 1947-10-14 | Diamond Chain & Mfg Company | Sprocket or gear |
| US2429001A (en) | 1946-12-28 | 1947-10-14 | Axel H Stone | Artificial hand |
| EP0092918B1 (en) | 1982-04-22 | 1988-10-19 | Imperial Chemical Industries Plc | Continuous release formulations |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8720833D0 (en) * | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| AU6430190A (en) | 1989-10-10 | 1991-05-16 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| CA2071867A1 (en) | 1989-11-06 | 1991-05-07 | Edith Mathiowitz | Method for producing protein microspheres |
| JPH06507404A (ja) | 1991-05-01 | 1994-08-25 | ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | 感染性の呼吸性疾患の治療方法 |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| EP0563475B1 (en) | 1992-03-25 | 2000-05-31 | Immunogen Inc | Cell binding agent conjugates of derivatives of CC-1065 |
| AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| DE4444135B4 (de) | 1994-12-11 | 2005-06-02 | Gerold Tebbe | Sauerstoff-Behandlungseinrichtung |
| ATE252894T1 (de) | 1995-01-05 | 2003-11-15 | Univ Michigan | Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| AU710347B2 (en) | 1995-08-31 | 1999-09-16 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| US5985320A (en) | 1996-03-04 | 1999-11-16 | The Penn State Research Foundation | Materials and methods for enhancing cellular internalization |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| DE69732306T2 (de) | 1997-01-16 | 2006-01-12 | Massachusetts Institute Of Technology, Cambridge | Zubereitung von partikelhaltigen arzneimitteln zur inhalation |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| RU2141483C1 (ru) | 1997-07-04 | 1999-11-20 | Небольсин Владимир Евгеньевич | Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| ES2198922T3 (es) | 1998-06-24 | 2004-02-01 | Advanced Inhalation Research, Inc. | Particulas porosas grandes emitadas por un inhalador. |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| HK1049997B (en) | 1999-11-24 | 2007-02-23 | Immunogen, Inc. | Cytotoxic agents comprising taxanes and their therapeutic use |
| AU767394C (en) | 1999-12-29 | 2005-04-21 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| US20050271663A1 (en) | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| JP5275566B2 (ja) | 2003-06-18 | 2013-08-28 | ザ スクリプス リサーチ インスティチュート | 反応性非天然アミノ酸遺伝コード付加 |
| AU2004273791A1 (en) | 2003-09-05 | 2005-03-31 | Genentech, Inc. | Antibodies with altered effector functions |
| US20060166319A1 (en) | 2004-08-13 | 2006-07-27 | Chan Michael K | Charging tRNA with pyrrolysine |
| US20060183888A1 (en) | 2004-08-13 | 2006-08-17 | Chan Michael K | Pyrrolysine synthesis and modification |
| AU2005277641A1 (en) * | 2004-08-16 | 2006-03-02 | Medimmune, Llc | Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| TR201808537T4 (tr) * | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| CA2580796C (en) | 2004-09-24 | 2013-03-26 | Amgen Inc. | Modified fc molecules having peptides inserted in internal loop regions |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| WO2008020827A2 (en) * | 2005-08-01 | 2008-02-21 | Biogen Idec Ma Inc. | Altered polypeptides, immunoconjugates thereof, and methods related thereto |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| KR20080080482A (ko) | 2005-09-07 | 2008-09-04 | 메디뮨 엘엘씨 | 독소가 컨쥬게이트된 ｅｐｈ 수용체 항체 |
| PT2032606E (pt) * | 2006-05-30 | 2014-02-05 | Genentech Inc | Anticorpos e imunoconjugados e respetivas utilizações |
| US20100297103A1 (en) | 2006-09-14 | 2010-11-25 | Medical & Biological Laboratories Co., Ltd. | Antibody having enhanced adcc activity and method for production thereof |
| PT2845866T (pt) | 2006-10-27 | 2017-08-09 | Genentech Inc | Anticorpos e imunoconjugados e utilizações dos mesmos |
| PL2099823T5 (pl) * | 2006-12-01 | 2023-02-20 | Seagen Inc. | Wariant środków wiążących cel i jego zastosowania |
| WO2008114011A2 (en) | 2007-03-19 | 2008-09-25 | Medimmune Limited | Fc polypeptide variants obtained by ribosome display methodology |
| PE20090245A1 (es) * | 2007-05-08 | 2009-03-17 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos |
| PT2474557E (pt) * | 2007-07-16 | 2014-12-03 | Genentech Inc | Anticorpos e imunoconjugados anti-cd79b e métodos de utilização |
| EP2206342A2 (en) * | 2007-09-10 | 2010-07-14 | Nxp B.V. | Method and apparatus for motion estimation and motion compensation in video image data |
| BRPI0818780A2 (pt) | 2007-10-19 | 2015-04-22 | Genentech Inc | Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos |
| KR20100107501A (ko) * | 2008-01-18 | 2010-10-05 | 메디뮨 엘엘씨 | 부위 특이적 접합을 위한 시스테인 조작 항체 |
| AU2009270988A1 (en) * | 2008-07-15 | 2010-01-21 | Genentech, Inc. | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| JP5542832B2 (ja) | 2008-10-24 | 2014-07-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 生合成的に製造したピロリン−カルボキシ−リシンならびにピロリン−カルボキシ−リシンおよびピロリシン基の化学誘導体化を介する部位特異的タンパク質修飾 |
| PE20120877A1 (es) * | 2009-04-01 | 2012-08-06 | Genentech Inc | ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS |
| CN101709047A (zh) | 2009-05-25 | 2010-05-19 | 华东理工大学 | 第二十二种天然氨基酸-吡咯赖氨酸的化学全合成方法 |
| EP2437785B1 (en) * | 2009-06-04 | 2015-02-25 | Novartis AG | METHODS FOR IDENTIFICATION OF SITES FOR IgG CONJUGATION |
| BRPI1015234A2 (en) * | 2009-06-22 | 2018-02-20 | Medimmune Llc | fc regions designed for site specific conjugation. |
| EP2451838A1 (en) | 2009-07-09 | 2012-05-16 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Stabilized immunoglobulin constant domains |
| GB0920127D0 (en) * | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| GB0920324D0 (en) * | 2009-11-19 | 2010-01-06 | Ucb Pharma Sa | Antibodies |
| CA2781682A1 (en) * | 2009-12-04 | 2011-06-09 | Genentech, Inc. | Multispecific antibodies, antibody analogs, compositions, and methods |
| EP2554669B1 (en) * | 2010-03-26 | 2018-09-19 | Kyowa Hakko Kirin Co., Ltd. | Novel antibody having modification site introduced therein, and antibody fragment |
| CA3220104A1 (en) * | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| GB201014033D0 (en) | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
| JP6014596B2 (ja) * | 2010-11-09 | 2016-10-25 | メディミューン，エルエルシー | 均一コンジュゲーションのための抗体足場 |
| EP2640727B1 (en) * | 2010-11-17 | 2015-05-13 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| EP3539982B1 (en) * | 2011-12-23 | 2025-02-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
| JP2015510200A (ja) | 2012-02-20 | 2015-04-02 | ノウリ コリア インコーポレイテッドＫｎｏｗｒｅ Ｋｏｒｅａ Ｉｎｃ． | 知識ユニットに基づいて教育サービスを提供するための方法、システム、およびコンピュータ読み取り可能な記録媒体 |
| SG11201407017WA (en) | 2012-06-04 | 2014-12-30 | Irm Llc | Site-specific labeling methods and molecules produced thereby |
| US9738724B2 (en) * | 2012-06-08 | 2017-08-22 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| WO2014124258A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
| EA201591465A1 (ru) | 2013-02-08 | 2015-12-30 | АйАрЭм ЭлЭлСи | Специфичные участки для модификации антител для получения иммуноконъюгатов |
| WO2014165277A2 (en) | 2013-03-12 | 2014-10-09 | Amgen Inc. | POTENT AND SELECTIVE INHIBITORS OF Nav1.7 |
| EP2968591A1 (en) | 2013-03-15 | 2016-01-20 | Novartis AG | Cell proliferation inhibitors and conjugates thereof |
| WO2015095301A2 (en) * | 2013-12-17 | 2015-06-25 | Irm Llc | Cytotoxic peptides and conjugates thereof |
| BR112016020065A2 (pt) | 2014-03-12 | 2018-02-20 | Novartis Ag | sítios específicos para modificar anticorpos para fazer imunoconjugados |
| US9884817B2 (en) * | 2014-06-13 | 2018-02-06 | Novartis Ag | Auristatin derivatives and conjugates thereof |
| WO2016020791A1 (en) * | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
| EP3215519A1 (en) * | 2014-11-06 | 2017-09-13 | Novartis AG | Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase |
| CR20180229A (es) * | 2015-10-29 | 2018-08-24 | Novartis Ag | Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll |
| CN117653740A (zh) * | 2016-12-21 | 2024-03-08 | 诺华股份有限公司 | 用于消融造血干细胞的抗体药物缀合物 |
| JOP20190187A1 (ar) * | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| AU2019409132B2 (en) * | 2018-12-21 | 2026-08-06 | Novartis Ag | Antibodies to PMEL17 and conjugates thereof |
| US11605302B2 (en) | 2020-11-10 | 2023-03-14 | Rockwell Collins, Inc. | Time-critical obstacle avoidance path planning in uncertain environments |
-
2014
- 2014-02-07 EA EA201591465A patent/EA201591465A1/ru unknown
- 2014-02-07 SG SG11201506025RA patent/SG11201506025RA/en unknown
- 2014-02-07 BR BR112015018899-0A patent/BR112015018899B1/pt active IP Right Grant
- 2014-02-07 ES ES14706739T patent/ES2874493T3/es active Active
- 2014-02-07 WO PCT/US2014/015393 patent/WO2014124316A2/en not_active Ceased
- 2014-02-07 DK DK14706739.1T patent/DK2953976T3/da active
- 2014-02-07 KR KR1020227032555A patent/KR102626525B1/ko active Active
- 2014-02-07 PT PT147067391T patent/PT2953976T/pt unknown
- 2014-02-07 SI SI201431831T patent/SI2953976T1/sl unknown
- 2014-02-07 CN CN201480017839.4A patent/CN105143271A/zh active Pending
- 2014-02-07 EP EP14706739.1A patent/EP2953976B1/en active Active
- 2014-02-07 MX MX2015010146A patent/MX2015010146A/es unknown
- 2014-02-07 HU HUE14706739A patent/HUE054443T2/hu unknown
- 2014-02-07 KR KR1020157024027A patent/KR20150115000A/ko not_active Ceased
- 2014-02-07 JP JP2015557139A patent/JP6609477B2/ja active Active
- 2014-02-07 CA CA2900755A patent/CA2900755C/en active Active
- 2014-02-07 AU AU2014214751A patent/AU2014214751B2/en active Active
- 2014-02-07 PL PL14706739T patent/PL2953976T3/pl unknown
- 2014-02-07 SG SG10201706468RA patent/SG10201706468RA/en unknown
- 2014-02-07 KR KR1020217031652A patent/KR102447350B1/ko active Active
- 2014-02-07 EP EP21164085.9A patent/EP3929217A3/en active Pending
- 2014-02-07 US US14/764,026 patent/US20160067351A1/en not_active Abandoned
- 2014-02-07 CN CN202210867143.7A patent/CN115925957A/zh active Pending
-
2015
- 2015-08-05 MX MX2022010324A patent/MX2022010324A/es unknown
- 2015-08-06 IL IL240406A patent/IL240406B/en active IP Right Grant
-
2017
- 2017-08-24 AU AU2017219059A patent/AU2017219059A1/en not_active Abandoned
-
2019
- 2019-12-03 US US16/701,576 patent/US11596695B2/en active Active
-
2023
- 2023-03-06 US US18/178,886 patent/US20230270876A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260139074A1 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| CN107849102B (zh) | 嵌合抗原受体组合物 | |
| US11458212B2 (en) | Molecular imaging of cancer cells in vivo | |
| JP6901493B2 (ja) | 抗ｂｃｍａポリペプチド及びタンパク質 | |
| JP5795463B2 (ja) | 血管内皮増殖因子に対する抗体と、２型ヒト上皮成長因子受容体に対する抗体を用いた腫瘍治療 | |
| JP2006502110A5 (enExample) | ||
| JP2019532056A5 (enExample) | ||
| JP2020533960A (ja) | 抗ｉｌ１ｒａｐ抗体 | |
| RU2016133846A (ru) | Конъюгат лиганд - цитотоксическое лекарственное средство, способ его получения и его применения | |
| JP2017510559A (ja) | 抗ＥＧＦＲｖＩＩＩ抗体およびその使用 | |
| CN118047832A (zh) | 与met结合的抗met抗体、双特异性抗原结合分子及其使用方法 | |
| JP2012100675A5 (enExample) | ||
| HRP20170743T1 (hr) | Anti-ceacam5 protutijela i njihova uporaba | |
| HRP20160190T1 (hr) | Protutijela anti-igf | |
| CA2866612A1 (en) | Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof | |
| JP2015501639A (ja) | 抗ｃｄ９８抗体およびその使用方法 | |
| JP2015529641A5 (enExample) | ||
| JP2015533832A (ja) | 抗Ｃ１６ｏｒｆ５４抗体およびその使用方法 | |
| JP2019534705A5 (enExample) | ||
| US20230270871A1 (en) | Markers for use in methods for treating cancers with antibody drug conjugates (adc) | |
| JP2017517507A5 (enExample) | ||
| KR20220054321A (ko) | 191p4d12 단백질에 결합하는 항체 약물 컨쥬게이트(adc)를 사용한 암의 치료 | |
| JP2026048890A (ja) | 抗体－薬物複合物及びｃｄｋ９阻害剤の組み合わせ | |
| JP2020524669A (ja) | 抗ｇｌｏｂｏ ｈ抗体を含有する抗体−薬物コンジュゲートおよびその使用 | |
| CN114514041A (zh) | 抗ptcra抗体-药物缀合物及其用途 |